Volume 2 Issue 9

封面解读

刘鹏

胡亚伟

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy has shown promise, but the underlying mechanisms remain unclear. To address the scarcity of tumor samples, researchers utilize patient-derived tumor cells to explore DMG heterogeneity. The epigenetic characteristics of DMG include a loss of H3K27me3 and a gain of H3K27ac. To overcome the limitations of traditional techniques, we developed high-throughputin situtagged immunoprecipitation sequencing (HiTIP-seq) utilizing InSMART, enabling 100 parallel assays from just 100 cells on a single chip. Using this new method, we analyzed epigenetic alterations in 3D cell cultures derived from DMG patients, discovering that combinations of epigenetic agents (such as panobinostat and tazemetostat) can reprogram histone modifications and drive transcriptome changes, notably upregulatingWIF1. HiTIP-seq provides a new tool for DMG research, showcasing hope in the fight against this deadly disease, and may ultimately lead to effective treatment options in the future.

目 录

导 读

1. Recent advances in surgical management strategies for hepatocellular carcinoma - ScienceDirectScienceDirect

通讯作者：周俭

HIGHLIGHTS

Due to different disease backgrounds, different surgical treatments for hepatocellular carcinoma (HCC) have been developed.

Enhanced visualization methods and artificial intelligence provide benefits to both surgical oncologists and HCC patients.

The emergence and evolution of new technologies have broken through the forbidden zone of HCC surgical treatment.

With the exploration of innovative clinical trials, the surgical management pattern of HCC may be continuously revolutionized.

引用：

Ding ZB, Shi YH, Chen JF, et al. Recent advances in surgical management strategies for hepatocellular carcinoma.hLife2024;2:439–453.

2. Discoidin domain receptor 1 as a potent therapeutic target in solid tumors

通讯作者：金腾川

文章讨论了人类跨膜蛋白盘状蛋白结构域受体1（DDR1）的结构、功能和病理特征，逐步揭示了DDR1在实体瘤微环境中的作用，并提出了其作为潜在的治疗靶点的可行性。

引用：

Bibi S, Zeng W, Zheng P, et al. Discoidin domain receptor 1 as a potent therapeutic target in solid tumors.hLife2024;2:454–466.

3. Surpassing the natural limits of serological diagnostic tests

通讯作者：D. William Provance Jr.

引用：

Provance DW Jr, da Matta Durans A, Lechuga GC, et al. Surpassing the natural limits of serological diagnostic tests.hLife2024;2:467–470.

4. HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy

通讯作者：刘鹏、章薇、胡亚伟

该研究基于微阵列芯片开发出一种高通量原位标记免疫沉淀测序技术（HiTIP-seq），不仅为弥漫性中线胶质瘤（Diffuse Midline Glioma, DMG）研究提供了新技术，更为其治疗新策略提供了科学依据。

引用：

Chen Z, Gao Q, Shang Y, et al. HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy.hLife2024;2:471–487.

5. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion

通讯作者：陈凌、李锋

引用：

Chen S, Zhang Z, Wang Q, et al. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion.hLife2024;2:488–491.